Business

Accenture Invests in Ryght AI to Help Life Sciences Companies Transform Clinical Research with Agentic AI

NEW YORK, December 11, 2025--Accenture has invested in Ryght AI, a platform provider that modernizes how clinical research is designed and executed for the life sciences industry.

articleAccenture PlcDecember 11, 20253/company/accenture-plc/news/accenture-invests-in-ryght-ai-to-help-life-sciences-companies-transform-clinical-research-with-agentic-ai
Accenture Invests in Ryght AI to Help Life Sciences Companies Transform Clinical Research with Agentic AI

About this update from Accenture Plc

[{"type":"image","alt":"Accenture has invested in Ryght AI, a platform provider that modernizes how clinical research is designed and executed for the life sciences industry.","displaySize":"","headline":null,"caption":"Accenture has invested in Ryght AI, a platform provider that modernizes how clinical research is designed and executed for the life sciences industry.","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":251,"url":"https://media.zenfs.com/en/business-wire.com/60ff4b109fa00249eb95a655240bf1c0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9dOL.DZvedtcW8kk9DqizA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/60ff4b109fa00249eb95a655240bf1c0","width":480,"height":251}},"lazy":false},{"type":"text","content":"NEW YORK, December 11, 2025--(BUSINESS WIRE)--Accenture (NYSE: ACN) has invested in Ryght AI, a platform provider that modernizes how clinical research is designed and executed for the life sciences industry. This investment, made through Accenture Ventures, will enable life sciences and clinical research companies to bring new treatments to patients faster by combining agentic AI with enterprise technology solutions.","length":421,"tagName":"p"},{"type":"text","content":"The clinical trial process is becoming increasingly complex, leading to major delays, especially with site selection and patient enrollment. As the cost of developing new drugs continues to rise, manual site selection can add weeks or months to each study, creating significant bottlenecks that slow down the entire development process and stall the introduction of many promising therapies.","length":391,"tagName":"p"},{"type":"text","content":"Ryght AI addresses these challenges through its AI Site Twin platform, which creates dynamic digital replicas of clinical research sites, capturing historical performance, patient demographics and operational data in real-time. These tools allow sponsors and contract research organizations to more easily identify the sites that best meet regulations and protocols, forecast enrollment more accurately and streamline site activation workflows.","length":444,"tagName":"p"},{"type":"text","content":"This investment and collaboration will combine Accenture’s deep industry, technology and data-engineering expertise with Ryght AI’s advanced...

More updates from Accenture Plc

Accentureclinical researchsite selectionRyght AIenterprise technology solutionsagentic AIlife sciences industryinvestment